Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study

Fig. 2

Kaplan Meier estimates of progression-free survival (PFS) and overall survival (OS) according to type of anlotinib treatment modes in patients with EGFR mutations A PFS in all EGFR mutated NSCLC patients; B PFS in the anlotinib monotherapy and combination therapy groups (P = 0.001); C OS in all EGFR mutated NSCLC patients; D OS in the anlotinib monotherapy and combination therapy groups (P = 0.223)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us